News

Wanbury Limited will hold a board meeting on Wednesday, November 04, 2026, to consider and approve the unaudited financial results (standalone & consolidated) for the second quarter and half year ended September 30, 2026, according to a regulatory filing. Trading in the company`s securities will be closed for directors, officers, key managerial personnel, and designated employees until 48 hours after the financial results are declared.

Wanbury will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Wanbury recently received �No DMF deficiency letter� from the office of USFDA (US Food and Drug Administration) for multiple ANDAs (Abbreviated New Drug Applications) with Metformin HCl API source of Wanbury for different formulations. Further, Wanbury expanded business opportunities in South Korea for one more API by filing the DMF. Wanbury is committed for supply of best APIs to the new market for well-being of human being.

Wanbury announced that a routine current Good Manufacturing Practices ( cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company`s facility at Tanuku, West Godavari District, Andhra Pradesh during the period from 13 July 2026 to 17 July 2026. At the conclusion of the inspection, the U.S.FDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time.

Wanbury announced the company has expanded regulatory submission for launch of new Active Pharmaceuticals Ingredients (APIs). For Diphenhydramine HCl, company submitted DMF to Malaysia and Singapore. The Company proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs. Company also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.